Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer.
The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small-cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.